JASPER THERAPEUTICS INC (JSPR) Fundamental Analysis & Valuation

NASDAQ:JSPR • US4718712023

Current stock price

1.05 USD
+0.12 (+12.61%)
At close:
1.05 USD
0 (0%)
After Hours:

This JSPR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. JSPR Profitability Analysis

1.1 Basic Checks

  • In the past year JSPR has reported negative net income.
  • In the past year JSPR has reported a negative cash flow from operations.
  • In the past 5 years JSPR always reported negative net income.
  • JSPR had a negative operating cash flow in each of the past 5 years.
JSPR Yearly Net Income VS EBIT VS OCF VS FCFJSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • JSPR's Return On Assets of -211.86% is on the low side compared to the rest of the industry. JSPR is outperformed by 89.15% of its industry peers.
  • With a Return On Equity value of -1826.09%, JSPR is not doing good in the industry: 82.56% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -211.86%
ROE -1826.09%
ROIC N/A
ROA(3y)-123%
ROA(5y)-95.93%
ROE(3y)-674.61%
ROE(5y)-434.52%
ROIC(3y)N/A
ROIC(5y)N/A
JSPR Yearly ROA, ROE, ROICJSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JSPR Yearly Profit, Operating, Gross MarginsJSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. JSPR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, JSPR has more shares outstanding
  • JSPR has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JSPR Yearly Shares OutstandingJSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
JSPR Yearly Total Debt VS Total AssetsJSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • JSPR has an Altman-Z score of -18.81. This is a bad value and indicates that JSPR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of JSPR (-18.81) is worse than 83.33% of its industry peers.
  • There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.81
ROIC/WACCN/A
WACCN/A
JSPR Yearly LT Debt VS Equity VS FCFJSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 2.62 indicates that JSPR has no problem at all paying its short term obligations.
  • JSPR has a Current ratio of 2.62. This is in the lower half of the industry: JSPR underperforms 68.22% of its industry peers.
  • A Quick Ratio of 2.62 indicates that JSPR has no problem at all paying its short term obligations.
  • JSPR has a Quick ratio of 2.62. This is in the lower half of the industry: JSPR underperforms 65.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 2.62
JSPR Yearly Current Assets VS Current LiabilitesJSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. JSPR Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.88% over the past year.
EPS 1Y (TTM)2.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, JSPR will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.60% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.04%
EPS Next 2Y25.75%
EPS Next 3Y20.47%
EPS Next 5Y12.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JSPR Yearly Revenue VS EstimatesJSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M
JSPR Yearly EPS VS EstimatesJSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. JSPR Valuation Analysis

4.1 Price/Earnings Ratio

  • JSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JSPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JSPR Price Earnings VS Forward Price EarningsJSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JSPR Per share dataJSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • JSPR's earnings are expected to grow with 20.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.75%
EPS Next 3Y20.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JSPR Dividend Analysis

5.1 Amount

  • No dividends for JSPR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JSPR Fundamentals: All Metrics, Ratios and Statistics

JASPER THERAPEUTICS INC

NASDAQ:JSPR (4/15/2026, 8:01:07 PM)

After market: 1.05 0 (0%)

1.05

+0.12 (+12.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-11
Inst Owners73.04%
Inst Owner Change0%
Ins Owners0.78%
Ins Owner Change0%
Market Cap29.40M
Revenue(TTM)N/A
Net Income(TTM)-75.80M
Analysts78.57
Price Target8.93 (750.48%)
Short Float %10.89%
Short Ratio6.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.49%
Min EPS beat(2)-0.88%
Max EPS beat(2)57.85%
EPS beat(4)1
Avg EPS beat(4)5.76%
Min EPS beat(4)-28.61%
Max EPS beat(4)57.85%
EPS beat(8)3
Avg EPS beat(8)1.34%
EPS beat(12)6
Avg EPS beat(12)1.99%
EPS beat(16)10
Avg EPS beat(16)7.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-30.92%
PT rev (3m)-30.92%
EPS NQ rev (1m)29.74%
EPS NQ rev (3m)29.74%
EPS NY rev (1m)18.5%
EPS NY rev (3m)21.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.08
P/tB 7.08
EV/EBITDA N/A
EPS(TTM)-4.72
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-2.76
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS0
BVpS0.15
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -211.86%
ROE -1826.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123%
ROA(5y)-95.93%
ROE(3y)-674.61%
ROE(5y)-434.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 2.62
Altman-Z -18.81
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.65%
Cap/Depr(5y)153.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.25%
EPS Next Y59.04%
EPS Next 2Y25.75%
EPS Next 3Y20.47%
EPS Next 5Y12.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.56%
EBIT Next 3Y-1.88%
EBIT Next 5YN/A
FCF growth 1Y-22.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.26%
OCF growth 3YN/A
OCF growth 5YN/A

JASPER THERAPEUTICS INC / JSPR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JASPER THERAPEUTICS INC (JSPR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to JSPR.


Can you provide the valuation status for JASPER THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to JASPER THERAPEUTICS INC (JSPR). This can be considered as Overvalued.


How profitable is JASPER THERAPEUTICS INC (JSPR) stock?

JASPER THERAPEUTICS INC (JSPR) has a profitability rating of 0 / 10.


Can you provide the financial health for JSPR stock?

The financial health rating of JASPER THERAPEUTICS INC (JSPR) is 5 / 10.